Format

Send to

Choose Destination
Mol Pharm. 2019 Jun 3;16(6):2838-2844. doi: 10.1021/acs.molpharmaceut.9b00078. Epub 2019 Apr 29.

Remodeling of the Tumor Microenvironment by a Chemokine/Anti-PD-L1 Nanobody Fusion Protein.

Author information

1
Program in Cellular and Molecular Medicine , Boston Children's Hospital , Boston , Massachusetts 02115 , United States.

Abstract

An optimal response to immune checkpoint blockade requires the presence of effector cells in the tumor microenvironment. We designed a PD-L1-targeted delivery strategy for chemokines, key molecules that drive leukocyte trafficking, to the tumor microenvironment, as a means of attracting the relevant leukocyte populations. This strategy combines a PD-L1-blocking single-domain antibody fragment (nanobody or VHH), a charge-engineered chemokine CCL21, and its subsequent characterization in a microfluidic device that resembles the tumor microenvironment. We show that the PD-L1-blocking VHH is a reliable fusion partner for the preparation of a functional chemokine fusion. Engineering the surface charge of CCL21 reduced its nonspecific binding to glycosaminoglycans, a property of chemokines that complicates their targeted delivery. Using a microfluidic assay, we show that it is possible to deliver a chemokine-VHH fusion to a PD-L1-positive environment and recruit effector cells.

KEYWORDS:

chemokine; delivery; immunotherapy; microfluidic device; nanobody

Supplemental Content

Full text links

Icon for American Chemical Society
Loading ...
Support Center